A similar getting was reported by Noth et al. such as IL-1, IL-2, IL-6, IL-8, TNF-, and IFN-have been recognized in psoriatic lesional pores and skin as compared to non-lesional and healthy pores and skin and serum levels of the subset of these cytokines are correlated with disease severity [4,5]. In individuals with rheumatoid arthritis, numerous cytokines such as TNF-, IL-1, IL-6, Rimeporide IL-8, and IFN-are produced and are functionally active in synovial tissues, leading to cytokine-driven joint inflammation and damage [6]. Ankylosing spondylitis is usually a chronic inflammatory condition of the spine, and serum levels of numerous cytokines have been found at increased levels in patients [7]. Due to the importance of cytokines in the pathogenesis of these diseases, anti-cytokine antibodies have been used as treatment strategies to restore the immune homeostasis. Increased intestinal permeability, also referred to as leaky gut, is usually often seen in chronic inflammatory conditions mentioned above. Previous studies have shown that some cytokines are able to directly damage the gut barrier function. Given this, it is possible that anti-cytokine antibodies may contribute to their clinical beneficial effects by modulating the gut barrier function in addition to regulating the immune responses. Here, we review the effects of clinically used anti-cytokine antibodies on gut barrier function and their associated mechanisms. == 2. Clinically Used Anti-Cytokine Antibodies == Anti-cytokine antibodies neutralise cytokine activities by blocking the conversation between cytokines and their receptors. Anti-cytokine antibodies currently approved by the Food and Drug Administration for clinical uses are outlined inTable 1. Anti-TNF-and anti-p40 subunit antibodies are used for the treatment of IBD. Currently, four anti-TNF-antibodies are available including infliximab, adalimumab, certolizumab, and golimumab. Infliximab and adalimumab are able to neutralise soluble, transmembrane, and receptor-bound TNF-, while certolizumab and golimumab are able to neutralise soluble CD34 and transmembrane forms of TNF-[810]. The use of anti-TNF-antibodies to treat IBD has been implicated for more than two decades, and anti-TNF-antibodies were useful in patients who are steroid unresponsive [11,12]. Ustekinumab, a human monoclonal antibody that targets the shared p40 subunit of IL-12 and IL-23, has also been approved for treating CD. == Table 1. == A list of clinically used anti-cytokine antibodies. Only Food and Drug Administration approved therapeutic brokers for clinical use are included. Data were obtained from URL:http://www.drugs.com(accessed on 08/04/2019). A number of cytokine neutralising antibodies have been approved in treating psoriasis, a chronic inflammatory skin disease. The candidate targets for such therapeutic antibodies include TNF-(infliximab, adalimumab, and certolizumab), IL-12 (ustekinumab), IL-23 (ustekinumab, guselkumab, and tildrakizumab), and IL-17 (ixekizumab, secukinumab, and brodalumab). Secukinumab which targets IL-17A/F is also used to treat ankylosing spondylitis and psoriatic arthritis. Rheumatoid arthritis, a chronic inflammatory disease affecting the joints, is usually another disease being treated with anti-cytokine therapies [13]. Therapeutic targets, TNF-and IL-6, are the two important cytokines involved in the Rimeporide pathogenesis of the disease. Tocilizumab and sarilumab, both targeting IL-6 receptors, have been approved for treating rheumatoid arthritis. == 3. Increased Intestinal Permeability in Diseases Treated with Anti-Cytokine Antibodies == Previous studies found that patients with chronic inflammatory and autoimmune diseases mentioned above usually have a compromised gut barrier function, indicated by abnormal permeation of non-metabolised sugar molecules, radioisotopes, and polyethylene glycols (Table 2). The leaky gut allows enhanced passages of luminal bacterial species and bacterial products such as toxins and antigens and is believed to contribute to the pathogenesis of chronic inflammatory and autoimmune diseases [1416]. == Table 2. == Increased intestinal permeability in chronic inflammatory and autoimmune diseases treated with anti-cytokine antibodies. IBD: inflammatory bowel disease; CD: Crohn’s disease; Rimeporide UC: ulcerative colitis. Patients with IBD, including both Crohn’s disease (CD) and ulcerative colitis (UC) which are the two major clinical forms of the disease, are known to have increased intestinal permeability, and increased intestinal.